Search

Your search keyword '"Puc, Matthew"' showing total 136 results
Start Over Author "Puc, Matthew"
136 results on '"Puc, Matthew"'

1. COVID-19 severity and cardiovascular outcomes in SARS-CoV-2-infected patients with cancer and cardiovascular disease.

Author

Moey, Melissa, Hennessy, Cassandra, French, Benjamin, Warner, Jeremy, Tucker, Matthew, Hausrath, Daniel, Shah, Dimpy, DeCara, Jeanne, Bakouny, Ziad, Labaki, Chris, Choueiri, Toni, Dent, Susan, Akhter, Nausheen, Ismail-Khan, Roohi, Tachiki, Lisa, Slosky, David, Polonsky, Tamar, Awosika, Joy, Crago, Audrey, Wise-Draper, Trisha, Balanchivadze, Nino, Hwang, Clara, Fecher, Leslie, Gomez, Cyndi, Hayes-Lattin, Brandon, Glover, Michael, Shah, Sumit, Gopalakrishnan, Dharmesh, Griffiths, Elizabeth, Kwon, Daniel, Koshkin, Vadim, Mahmood, Sana, Bashir, Babar, Nonato, Taylor, Razavi, Pedram, McKay, Rana, Nagaraj, Gayathri, Oligino, Eric, Puc, Matthew, Tregubenko, Polina, Wulff-Burchfield, Elizabeth, Xie, Zhuoer, Halfdanarson, Thorvardur, Farmakiotis, Dimitrios, Klein, Elizabeth, Robilotti, Elizabeth, Riely, Gregory, Durand, Jean-Bernard, Hayek, Salim, Kondapalli, Lavanya, Berg, Stephanie, OConnor, Timothy, Bilen, Mehmet, Castellano, Cecilia, Accordino, Melissa, Sibel, Blau, Weissmann, Lisa, Jani, Chinmay, Flora, Daniel, Rudski, Lawrence, Dutra, Miriam, Nathaniel, Bouganim, Ruíz-García, Erika, Vilar-Compte, Diana, Gupta, Shilpa, Morgans, Alicia, and Nohria, Anju

Subjects
COVID-19 outcomes, Cancer, Cardio-oncology, Cardiovascular disease
Abstract

BACKGROUND: Data regarding outcomes among patients with cancer and co-morbid cardiovascular disease (CVD)/cardiovascular risk factors (CVRF) after SARS-CoV-2 infection are limited. OBJECTIVES: To compare Coronavirus disease 2019 (COVID-19) related complications among cancer patients with and without co-morbid CVD/CVRF. METHODS: Retrospective cohort study of patients with cancer and laboratory-confirmed SARS-CoV-2, reported to the COVID-19 and Cancer Consortium (CCC19) registry from 03/17/2020 to 12/31/2021. CVD/CVRF was defined as established CVD or no established CVD, male ≥ 55 or female ≥ 60 years, and one additional CVRF. The primary endpoint was an ordinal COVID-19 severity outcome including need for hospitalization, supplemental oxygen, intensive care unit (ICU), mechanical ventilation, ICU or mechanical ventilation plus vasopressors, and death. Secondary endpoints included incident adverse CV events. Ordinal logistic regression models estimated associations of CVD/CVRF with COVID-19 severity. Effect modification by recent cancer therapy was evaluated. RESULTS: Among 10,876 SARS-CoV-2 infected patients with cancer (median age 65 [IQR 54-74] years, 53% female, 52% White), 6253 patients (57%) had co-morbid CVD/CVRF. Co-morbid CVD/CVRF was associated with higher COVID-19 severity (adjusted OR: 1.25 [95% CI 1.11-1.40]). Adverse CV events were significantly higher in patients with CVD/CVRF (all p

Published
2023

2. Impact of COVID-19 in patients on active melanoma therapy and with history of melanoma.

Author

Johnson, Douglas B, Atkins, Michael B, Hennessy, Cassandra, Wise-Draper, Trisha, Heilman, Hannah, Awosika, Joy, Bakouny, Ziad, Labaki, Chris, Saliby, Renee Maria, Hwang, Clara, Singh, Sunny RK, Balanchivadze, Nino, Friese, Christopher R, Fecher, Leslie A, Yoon, James J, Hayes-Lattin, Brandon, Bilen, Mehmet A, Castellano, Cecilia A, Lyman, Gary H, Tachiki, Lisa, Shah, Sumit A, Glover, Michael J, Flora, Daniel B, Wulff-Burchfield, Elizabeth, Kasi, Anup, Abbasi, Saqib H, Farmakiotis, Dimitrios, Viera, Kendra, Klein, Elizabeth J, Weissman, Lisa B, Jani, Chinmay, Puc, Matthew, Fahey, Catherine C, Reuben, Daniel Y, Mishra, Sanjay, Beeghly-Fadiel, Alicia, French, Benjamin, Warner, Jeremy L, and COVID-19 and Cancer Consortium

Subjects
COVID-19 and Cancer Consortium, Humans, Melanoma, Multiple Organ Failure, Immunotherapy, COVID-19, Cancer, Immune therapy, Targeted therapy, Rehabilitation, Clinical Research, Lung, Rare Diseases, Good Health and Well Being, Oncology and Carcinogenesis, Public Health and Health Services, Oncology & Carcinogenesis
Abstract

IntroductionCOVID-19 particularly impacted patients with co-morbid conditions, including cancer. Patients with melanoma have not been specifically studied in large numbers. Here, we sought to identify factors that associated with COVID-19 severity among patients with melanoma, particularly assessing outcomes of patients on active targeted or immune therapy.MethodsUsing the COVID-19 and Cancer Consortium (CCC19) registry, we identified 307 patients with melanoma diagnosed with COVID-19. We used multivariable models to assess demographic, cancer-related, and treatment-related factors associated with COVID-19 severity on a 6-level ordinal severity scale. We assessed whether treatment was associated with increased cardiac or pulmonary dysfunction among hospitalized patients and assessed mortality among patients with a history of melanoma compared with other cancer survivors.ResultsOf 307 patients, 52 received immunotherapy (17%), and 32 targeted therapy (10%) in the previous 3 months. Using multivariable analyses, these treatments were not associated with COVID-19 severity (immunotherapy OR 0.51, 95% CI 0.19 - 1.39; targeted therapy OR 1.89, 95% CI 0.64 - 5.55). Among hospitalized patients, no signals of increased cardiac or pulmonary organ dysfunction, as measured by troponin, brain natriuretic peptide, and oxygenation were noted. Patients with a history of melanoma had similar 90-day mortality compared with other cancer survivors (OR 1.21, 95% CI 0.62 - 2.35).ConclusionsMelanoma therapies did not appear to be associated with increased severity of COVID-19 or worsening organ dysfunction. Patients with history of melanoma had similar 90-day survival following COVID-19 compared with other cancer survivors.

Published
2023

3. Clinical characteristics, racial inequities, and outcomes in patients with breast cancer and COVID-19: A COVID-19 and cancer consortium (CCC19) cohort study

Author

Nagaraj, Gayathri, Vinayak, Shaveta, Khaki, Ali Raza, Sun, Tianyi, Kuderer, Nicole M, Aboulafia, David M, Acoba, Jared D, Awosika, Joy, Bakouny, Ziad, Balmaceda, Nicole B, Bao, Ting, Bashir, Babar, Berg, Stephanie, Bilen, Mehmet A, Bindal, Poorva, Blau, Sibel, Bodin, Brianne E, Borno, Hala T, Castellano, Cecilia, Choi, Horyun, Deeken, John, Desai, Aakash, Edwin, Natasha, Feldman, Lawrence E, Flora, Daniel B, Friese, Christopher R, Galsky, Matthew D, Gonzalez, Cyndi J, Grivas, Petros, Gupta, Shilpa, Haynam, Marcy, Heilman, Hannah, Hershman, Dawn L, Hwang, Clara, Jani, Chinmay, Jhawar, Sachin R, Joshi, Monika, Kaklamani, Virginia, Klein, Elizabeth J, Knox, Natalie, Koshkin, Vadim S, Kulkarni, Amit A, Kwon, Daniel H, Labaki, Chris, Lammers, Philip E, Lathrop, Kate I, Lewis, Mark A, Li, Xuanyi, de Lima Lopes, Gilbert, Lyman, Gary H, Makower, Della F, Mansoor, Abdul-Hai, Markham, Merry-Jennifer, Mashru, Sandeep H, McKay, Rana R, Messing, Ian, Mico, Vasil, Nadkarni, Rajani, Namburi, Swathi, Nguyen, Ryan H, Nonato, Taylor Kristian, O'Connor, Tracey Lynn, Panagiotou, Orestis A, Park, Kyu, Patel, Jaymin M, Patel, Kanishka GopikaBimal, Peppercorn, Jeffrey, Polimera, Hyma, Puc, Matthew, Rao, Yuan James, Razavi, Pedram, Reid, Sonya A, Riess, Jonathan W, Rivera, Donna R, Robson, Mark, Rose, Suzanne J, Russ, Atlantis D, Schapira, Lidia, Shah, Pankil K, Shanahan, M Kelly, Shapiro, Lauren C, Smits, Melissa, Stover, Daniel G, Streckfuss, Mitrianna, Tachiki, Lisa, Thompson, Michael A, Tolaney, Sara M, Weissmann, Lisa B, Wilson, Grace, Wotman, Michael T, Wulff-Burchfield, Elizabeth M, Mishra, Sanjay, French, Benjamin, Warner, Jeremy L, Lustberg, Maryam B, Accordino, Melissa K, and Shah, Dimpy P

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Clinical Research, Coronaviruses, Infectious Diseases, Cancer, Emerging Infectious Diseases, Breast Cancer, Lung, Women's Health, Good Health and Well Being, United States, Humans, Female, Middle Aged, COVID-19, SARS-CoV-2, Cohort Studies, Breast Neoplasms, Retrospective Studies, COVID-19 and Cancer Consortium, breast cancer, epidemiology, global health, human, oncology, pandemic, racial inequities, Biochemistry and Cell Biology, Biological sciences, Biomedical and clinical sciences, Health sciences
Abstract

BackgroundLimited information is available for patients with breast cancer (BC) and coronavirus disease 2019 (COVID-19), especially among underrepresented racial/ethnic populations.MethodsThis is a COVID-19 and Cancer Consortium (CCC19) registry-based retrospective cohort study of females with active or history of BC and laboratory-confirmed severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection diagnosed between March 2020 and June 2021 in the US. Primary outcome was COVID-19 severity measured on a five-level ordinal scale, including none of the following complications, hospitalization, intensive care unit admission, mechanical ventilation, and all-cause mortality. Multivariable ordinal logistic regression model identified characteristics associated with COVID-19 severity.Results1383 female patient records with BC and COVID-19 were included in the analysis, the median age was 61 years, and median follow-up was 90 days. Multivariable analysis revealed higher odds of COVID-19 severity for older age (aOR per decade, 1.48 [95% CI, 1.32-1.67]); Black patients (aOR 1.74; 95 CI 1.24-2.45), Asian Americans and Pacific Islander patients (aOR 3.40; 95 CI 1.70-6.79) and Other (aOR 2.97; 95 CI 1.71-5.17) racial/ethnic groups; worse ECOG performance status (ECOG PS ≥2: aOR, 7.78 [95% CI, 4.83-12.5]); pre-existing cardiovascular (aOR, 2.26 [95% CI, 1.63-3.15])/pulmonary comorbidities (aOR, 1.65 [95% CI, 1.20-2.29]); diabetes mellitus (aOR, 2.25 [95% CI, 1.66-3.04]); and active and progressing cancer (aOR, 12.5 [95% CI, 6.89-22.6]). Hispanic ethnicity, timing, and type of anti-cancer therapy modalities were not significantly associated with worse COVID-19 outcomes. The total all-cause mortality and hospitalization rate for the entire cohort was 9% and 37%, respectively however, it varied according to the BC disease status.ConclusionsUsing one of the largest registries on cancer and COVID-19, we identified patient and BC-related factors associated with worse COVID-19 outcomes. After adjusting for baseline characteristics, underrepresented racial/ethnic patients experienced worse outcomes compared to non-Hispanic White patients.FundingThis study was partly supported by National Cancer Institute grant number P30 CA068485 to Tianyi Sun, Sanjay Mishra, Benjamin French, Jeremy L Warner; P30-CA046592 to Christopher R Friese; P30 CA023100 for Rana R McKay; P30-CA054174 for Pankil K Shah and Dimpy P Shah; KL2 TR002646 for Pankil Shah and the American Cancer Society and Hope Foundation for Cancer Research (MRSG-16-152-01-CCE) and P30-CA054174 for Dimpy P Shah. REDCap is developed and supported by Vanderbilt Institute for Clinical and Translational Research grant support (UL1 TR000445 from NCATS/NIH). The funding sources had no role in the writing of the manuscript or the decision to submit it for publication.Clinical trial numberCCC19 registry is registered on ClinicalTrials.gov, NCT04354701.

Published
2023

4. Patients recently treated for B-lymphoid malignancies show increased risk of severe COVID-19: a CCC19 registry analysisImpact of B-cell malignancy therapy on COVID-19 outcomes

Author

Rubinstein, Samuel M, Bhutani, Divaya, Lynch, Ryan C, Hsu, Chih-Yuan, Shyr, Yu, Advani, Shailesh, Mesa, Ruben A, Mishra, Sanjay, Mundt, Daniel P, Shah, Dimpy P, Sica, R Alejandro, Stockerl-Goldstein, Keith E, Stratton, Catherine, Weiss, Matthias, Beeghly-Fadiel, Alicia, Accordino, Melissa, Assouline, Sarit E, Awosika, Joy, Bakouny, Ziad, Bashir, Babar, Berg, Stephanie, Bilen, Mehmet Asim, Castellano, Cecilia A, Cogan, Jacob C, Kc, Devendra, Friese, Christopher R, Gupta, Shilpa, Hausrath, Daniel, Hwang, Clara, Johnson, Nathalie A, Joshi, Monika, Kasi, Anup, Klein, Elizabeth J, Koshkin, Vadim S, Kuderer, Nicole M, Kwon, Daniel H, Labaki, Chris, Latif, Tahir, Lau, Eric, Li, Xuanyi, Lyman, Gary H, McKay, Rana R, Nagaraj, Gayathri, Nizam, Amanda, Nonato, Taylor K, Olszewski, Adam J, Polimera, Hyma V, Portuguese, Andrew J, Puc, Matthew M, Razavi, Pedram, Rosovski, Rachel, Schmidt, Andrew, Shah, Sumit A, Shastri, Aditi, Su, Christopher, Torka, Pallawi, Wise-Draper, Trisha M, Zubiri, Leyre, Warner, Jeremy L, and Thompson, Michael A

Subjects
Rare Diseases, Clinical Research, Prevention, Cancer, Aetiology, 2.1 Biological and endogenous factors, COVID-19, COVID-19 Testing, Humans, Lymphatic Diseases, Neoplasms, Risk Factors, SARS-CoV-2, COVID-19 and Cancer Consortium
Abstract

Patients with B-lymphoid malignancies have been consistently identified as a population at high risk of severe COVID-19. Whether this is exclusively due to cancer-related deficits in humoral and cellular immunity, or whether risk of severe COVID-19 is increased by anticancer therapy, is uncertain. Using data derived from the COVID-19 and Cancer Consortium (CCC19), we show that patients treated for B-lymphoid malignancies have an increased risk of severe COVID-19 compared with control populations of patients with non-B-lymphoid malignancies. Among patients with B-lymphoid malignancies, those who received anticancer therapy within 12 months of COVID-19 diagnosis experienced increased COVID-19 severity compared with patients with non-recently treated B-lymphoid malignancies, after adjustment for cancer status and several other prognostic factors. Our findings suggest that patients recently treated for a B-lymphoid malignancy are at uniquely high risk for severe COVID-19.SignificanceOur study suggests that recent therapy for a B-lymphoid malignancy is an independent risk factor for COVID-19 severity. These findings provide rationale to develop mitigation strategies targeted at the uniquely high-risk population of patients with recently treated B-lymphoid malignancies. This article is highlighted in the In This Issue feature, p. 171.

Published
2022

5. Geriatric risk factors for serious COVID-19 outcomes among older adults with cancer: a cohort study from the COVID-19 and Cancer Consortium

Author

Elkrief, Arielle, Hennessy, Cassandra, Kuderer, Nicole M, Rubinstein, Samuel M, Wulff-Burchfield, Elizabeth, Rosovsky, Rachel P, Vega-Luna, Karen, Thompson, Michael A, Panagiotou, Orestis A, Desai, Aakash, Rivera, Donna R, Khaki, Ali Raza, Tachiki, Lisa, Lynch, Ryan C, Stratton, Catherine, Elias, Rawad, Batist, Gerald, Kasi, Anup, Shah, Dimpy P, Bakouny, Ziad, Cabal, Angelo, Clement, Jessica, Crowell, Jennifer, Dixon, Becky, Friese, Christopher R, Fry, Stacy L, Grover, Punita, Gulati, Shuchi, Gupta, Shilpa, Hwang, Clara, Khan, Hina, Kim, Soo Jung, Klein, Elizabeth J, Labaki, Chris, McKay, Rana R, Nizam, Amanda, Pennell, Nathan A, Puc, Matthew, Schmidt, Andrew L, Shahrokni, Armin, Shaya, Justin A, Su, Christopher T, Wall, Sarah, Williams, Nicole, Wise-Draper, Trisha M, Mishra, Sanjay, Grivas, Petros, French, Benjamin, Warner, Jeremy L, Wildes, Tanya M, and Consortium, COVID-19 and Cancer

Subjects
Epidemiology, Public Health, Health Sciences, Clinical Research, Aging, Cancer, Prevention, Good Health and Well Being, Aged, COVID-19, COVID-19 Testing, Cohort Studies, Humans, Middle Aged, Neoplasms, Risk Factors, SARS-CoV-2, COVID-19 and Cancer Consortium, Public health
Abstract

BackgroundOlder age is associated with poorer outcomes of SARS-CoV-2 infection, although the heterogeneity of ageing results in some older adults being at greater risk than others. The objective of this study was to quantify the association of a novel geriatric risk index, comprising age, modified Charlson comorbidity index, and Eastern Cooperative Oncology Group performance status, with COVID-19 severity and 30-day mortality among older adults with cancer.MethodsIn this cohort study, we enrolled patients aged 60 years and older with a current or previous cancer diagnosis (excluding those with non-invasive cancers and premalignant or non-malignant conditions) and a current or previous laboratory-confirmed COVID-19 diagnosis who reported to the COVID-19 and Cancer Consortium (CCC19) multinational, multicentre, registry between March 17, 2020, and June 6, 2021. Patients were also excluded for unknown age, missing data resulting in unknown geriatric risk measure, inadequate data quality, or incomplete follow-up resulting in unknown COVID-19 severity. The exposure of interest was the CCC19 geriatric risk index. The primary outcome was COVID-19 severity and the secondary outcome was 30-day all-cause mortality; both were assessed in the full dataset. Adjusted odds ratios (ORs) and 95% CIs were estimated from ordinal and binary logistic regression models.Findings5671 patients with cancer and COVID-19 were included in the analysis. Median follow-up time was 56 days (IQR 22-120), and median age was 72 years (IQR 66-79). The CCC19 geriatric risk index identified 2365 (41·7%) patients as standard risk, 2217 (39·1%) patients as intermediate risk, and 1089 (19·2%) as high risk. 36 (0·6%) patients were excluded due to non-calculable geriatric risk index. Compared with standard-risk patients, high-risk patients had significantly higher COVID-19 severity (adjusted OR 7·24; 95% CI 6·20-8·45). 920 (16·2%) of 5671 patients died within 30 days of a COVID-19 diagnosis, including 161 (6·8%) of 2365 standard-risk patients, 409 (18·5%) of 2217 intermediate-risk patients, and 350 (32·1%) of 1089 high-risk patients. High-risk patients had higher adjusted odds of 30-day mortality (adjusted OR 10·7; 95% CI 8·54-13·5) than standard-risk patients.InterpretationThe CCC19 geriatric risk index was strongly associated with COVID-19 severity and 30-day mortality. Our CCC19 geriatric risk index, based on readily available clinical factors, might provide clinicians with an easy-to-use risk stratification method to identify older adults most at risk for severe COVID-19 as well as mortality.FundingUS National Institutes of Health National Cancer Institute Cancer Center.

Published
2022

6. Coinfections in Patients With Cancer and COVID-19: A COVID-19 and Cancer Consortium (CCC19) Study

Author

Satyanarayana, Gowri, Enriquez, Kyle T, Sun, Tianyi, Klein, Elizabeth J, Abidi, Maheen, Advani, Shailesh M, Awosika, Joy, Bakouny, Ziad, Bashir, Babar, Berg, Stephanie, Bernardes, Marilia, Egan, Pamela C, Elkrief, Arielle, Feldman, Lawrence E, Friese, Christopher R, Goel, Shipra, Gomez, Cyndi Gonzalez, Grant, Keith L, Griffiths, Elizabeth A, Gulati, Shuchi, Gupta, Shilpa, Hwang, Clara, Jain, Jayanshu, Jani, Chinmay, Kaltsas, Anna, Kasi, Anup, Khan, Hina, Knox, Natalie, Koshkin, Vadim S, Kwon, Daniel H, Labaki, Chris, Lyman, Gary H, McKay, Rana R, McNair, Christopher, Nagaraj, Gayathri, Nakasone, Elizabeth S, Nguyen, Ryan, Nonato, Taylor K, Olszewski, Adam J, Panagiotou, Orestis A, Puc, Matthew, Razavi, Pedram, Robilotti, Elizabeth V, Santos-Dutra, Miriam, Schmidt, Andrew L, Shah, Dimpy P, Shah, Sumit A, Vieira, Kendra, Weissmann, Lisa B, Wise-Draper, Trisha M, Wu, Ulysses, Wu, Julie Tsu-Yu, Choueiri, Toni K, Mishra, Sanjay, Warner, Jeremy L, French, Benjamin, and Farmakiotis, Dimitrios

Subjects
Biomedical and Clinical Sciences, Oncology and Carcinogenesis, Cancer, Infectious Diseases, Prevention, Lung, Clinical Research, Emerging Infectious Diseases, 2.2 Factors relating to the physical environment, Aetiology, Infection, Good Health and Well Being, bacterial infections, CAPA, COVID-19, mucormycoses, viral infections, Clinical sciences, Medical microbiology
Abstract

BackgroundThe frequency of coinfections and their association with outcomes have not been adequately studied among patients with cancer and coronavirus disease 2019 (COVID-19), a high-risk group for coinfection.MethodsWe included adult (≥18 years) patients with active or prior hematologic or invasive solid malignancies and laboratory-confirmed severe acute respiratory syndrome coronavirus 2 (SARS-COV-2) infection, using data from the COVID-19 and Cancer Consortium (CCC19, NCT04354701). We captured coinfections within ±2 weeks from diagnosis of COVID-19, identified factors cross-sectionally associated with risk of coinfection, and quantified the association of coinfections with 30-day mortality.ResultsAmong 8765 patients (hospitalized or not; median age, 65 years; 47.4% male), 16.6% developed coinfections: 12.1% bacterial, 2.1% viral, 0.9% fungal. An additional 6.4% only had clinical diagnosis of a coinfection. The adjusted risk of any coinfection was positively associated with age >50 years, male sex, cardiovascular, pulmonary, and renal comorbidities, diabetes, hematologic malignancy, multiple malignancies, Eastern Cooperative Oncology Group Performance Status, progressing cancer, recent cytotoxic chemotherapy, and baseline corticosteroids; the adjusted risk of superinfection was positively associated with tocilizumab administration. Among hospitalized patients, high neutrophil count and C-reactive protein were positively associated with bacterial coinfection risk, and high or low neutrophil count with fungal coinfection risk. Adjusted mortality rates were significantly higher among patients with bacterial (odds ratio [OR], 1.61; 95% CI, 1.33-1.95) and fungal (OR, 2.20; 95% CI, 1.28-3.76) coinfections.ConclusionsViral and fungal coinfections are infrequent among patients with cancer and COVID-19, with the latter associated with very high mortality rates. Clinical and laboratory parameters can be used to guide early empiric antimicrobial therapy, which may improve clinical outcomes.

Published
2022

7. Disparities in outcomes between Black and White patients in North America with thoracic malignancies and COVID-19 infection (TERAVOLT)

Author

Burns, Laura, Hsu, Chih-Yuan, Whisenant, Jennifer G., Marmarelis, Melina E., Presley, Carolyn J., Reckamp, Karen L., Khan, Hina, Jo Fidler, Mary, Bestvina, Christine M., Brahmer, Julie, Puri, Sonam, Patel, Jyoti D., Halmos, Balazs, Hirsch, Fred R., Liu, Stephen V., Costa, Daniel B., Goldberg, Sarah B., Feldman, Lawrence E., Mamdani, Hirva, Puc, Matthew, Mansfield, Aaron S., Islam, Nahida, Scilla, Katherine A., Garassino, Marina C., Horn, Leora, Peters, Solange, Wakelee, Heather A., Charlot, Marjory, and Tapan, Umit

Published
2023
Full Text
View/download PDF

8. Breakthrough SARS-CoV-2 infections among patients with cancer following two and three doses of COVID-19 mRNA vaccines: a retrospective observational study from the COVID-19 and Cancer Consortium

Author

Choueiri, Toni K., Labaki, Chris, Bakouny, Ziad, Hsu, Chih-Yuan, Schmidt, Andrew L., de Lima Lopes, Gilberto, Jr., Hwang, Clara, Singh, Sunny R.K., Jani, Chinmay, Weissmann, Lisa B., Griffiths, Elizabeth A., Halabi, Susan, Wu, Ulysses, Berg, Stephanie, O'Connor, Timothy E., Wise-Draper, Trisha M., Panagiotou, Orestis A., Klein, Elizabeth J., Joshi, Monika, Yared, Fares, Dutra, Miriam Santos, Gatson, Na Tosha N., Blau, Sibel, Singh, Harpreet, Nanchal, Rahul, McKay, Rana R., Nonato, Taylor K., Quinn, Ryann, Rubinstein, Samuel M., Puc, Matthew, Mavromatis, Blanche H., Vikas, Praveen, Faller, Bryan, Zaren, Howard A., Del Prete, Salvatore, Russell, Karen, Reuben, Daniel Y., Accordino, Melissa K., Friese, Christopher R., Mishra, Sanjay, Rivera, Donna R., Shyr, Yu, Farmakiotis, Dimitrios, and Warner, Jeremy L.

Published
2023
Full Text
View/download PDF

9. Brief Report: Impact of anti-cancer treatments on outcomes of COVID-19 in patients with thoracic cancers: a CCC19 registry analysis

Author

Kulkarni, Amit A., primary, Hennessy, Cassandra, additional, Wislon, Grace, additional, Ramesh, Vidhyalakshmi, additional, Hwang, Clara, additional, Joy, Awosika, additional, Bakouny, Ziad, additional, Khan, Hina, additional, Vilar-Compte, Diana, additional, McKay, Rana, additional, Jani, Chinmay, additional, Weissmann, Lisa, additional, Griffiths, Elizabeth, additional, Batist, Gerald, additional, Bouganim, Nathaniel, additional, Mavromatis, Blanche, additional, Bashir, Babar, additional, Nguyen, Ryan H., additional, Riess, Jonathan W., additional, Puc, Matthew, additional, Kasi, Anup, additional, Berg, Stephanie, additional, Castillo, Dan Ran, additional, Hayes-Lattin, Brandon, additional, Hosmer, Wylie, additional, Flora, Daniel, additional, Mishra, Sanjay, additional, French, Benjamin, additional, Warner, Jeremy L., additional, Lopes, Gilberto, additional, Peters, Solange, additional, and Florez, Narjust, additional

Published
2024
Full Text
View/download PDF

10. Author response: Clinical characteristics, racial inequities, and outcomes in patients with breast cancer and COVID-19: A COVID-19 and cancer consortium (CCC19) cohort study

Author

Nagaraj, Gayathri, primary, Vinayak, Shaveta, additional, Khaki, Ali Raza, additional, Sun, Tianyi, additional, Kuderer, Nicole M, additional, Aboulafia, David M, additional, Acoba, Jared D, additional, Awosika, Joy, additional, Bakouny, Ziad, additional, Balmaceda, Nicole B, additional, Bao, Ting, additional, Bashir, Babar, additional, Berg, Stephanie, additional, Bilen, Mehmet A, additional, Bindal, Poorva, additional, Blau, Sibel, additional, Bodin, Brianne E, additional, Borno, Hala T, additional, Castellano, Cecilia, additional, Choi, Horyun, additional, Deeken, John, additional, Desai, Aakash, additional, Edwin, Natasha, additional, Feldman, Lawrence E, additional, Flora, Daniel B, additional, Friese, Christopher R, additional, Galsky, Matthew D, additional, Gonzalez, Cyndi J, additional, Grivas, Petros, additional, Gupta, Shilpa, additional, Haynam, Marcy, additional, Heilman, Hannah, additional, Hershman, Dawn L, additional, Hwang, Clara, additional, Jani, Chinmay, additional, Jhawar, Sachin R, additional, Joshi, Monika, additional, Kaklamani, Virginia, additional, Klein, Elizabeth J, additional, Knox, Natalie, additional, Koshkin, Vadim S, additional, Kulkarni, Amit A, additional, Kwon, Daniel H, additional, Labaki, Chris, additional, Lammers, Philip E, additional, Lathrop, Kate I, additional, Lewis, Mark A, additional, Li, Xuanyi, additional, Lopes, Gilbert de Lima, additional, Lyman, Gary H, additional, Makower, Della F, additional, Mansoor, Abdul-Hai, additional, Markham, Merry-Jennifer, additional, Mashru, Sandeep H, additional, McKay, Rana R, additional, Messing, Ian, additional, Mico, Vasil, additional, Nadkarni, Rajani, additional, Namburi, Swathi, additional, Nguyen, Ryan H, additional, Nonato, Taylor Kristian, additional, O'Connor, Tracey Lynn, additional, Panagiotou, Orestis A, additional, Park, Kyu, additional, Patel, Jaymin M, additional, Patel, Kanishka GopikaBimal, additional, Peppercorn, Jeffrey, additional, Polimera, Hyma, additional, Puc, Matthew, additional, Rao, Yuan James, additional, Razavi, Pedram, additional, Reid, Sonya A, additional, Riess, Jonathan W, additional, Rivera, Donna R, additional, Robson, Mark, additional, Rose, Suzanne J, additional, Russ, Atlantis D, additional, Schapira, Lidia, additional, Shah, Pankil K, additional, Shanahan, M Kelly, additional, Shapiro, Lauren C, additional, Smits, Melissa, additional, Stover, Daniel G, additional, Streckfuss, Mitrianna, additional, Tachiki, Lisa, additional, Thompson, Michael A, additional, Tolaney, Sara M, additional, Weissmann, Lisa B, additional, Wilson, Grace, additional, Wotman, Michael T, additional, Wulff-Burchfield, Elizabeth M, additional, Mishra, Sanjay, additional, French, Benjamin, additional, Warner, Jeremy L, additional, Lustberg, Maryam B, additional, Accordino, Melissa K, additional, and Shah, Dimpy P, additional

Published
2023
Full Text
View/download PDF

11. COVID-19 severity and cardiovascular outcomes in SARS-CoV-2-infected patients with cancer and cardiovascular disease

Author

Moey, Melissa Y.Y., primary, Hennessy, Cassandra, additional, French, Benjamin, additional, Warner, Jeremy L., additional, Tucker, Matthew D., additional, Hausrath, Daniel J., additional, Shah, Dimpy P., additional, DeCara, Jeanne M., additional, Bakouny, Ziad, additional, Labaki, Chris, additional, Choueiri, Toni K., additional, Dent, Susan, additional, Akhter, Nausheen, additional, Ismail-Khan, Roohi, additional, Tachiki, Lisa, additional, Slosky, David, additional, Polonsky, Tamar S., additional, Awosika, Joy A., additional, Crago, Audrey, additional, Wise-Draper, Trisha, additional, Balanchivadze, Nino, additional, Hwang, Clara, additional, Fecher, Leslie A., additional, Gomez, Cyndi Gonzalez, additional, Hayes-Lattin, Brandon, additional, Glover, Michael J., additional, Shah, Sumit A., additional, Gopalakrishnan, Dharmesh, additional, Griffiths, Elizabeth A., additional, Kwon, Daniel H., additional, Koshkin, Vadim S., additional, Mahmood, Sana, additional, Bashir, Babar, additional, Nonato, Taylor, additional, Razavi, Pedram, additional, McKay, Rana R., additional, Nagaraj, Gayathri, additional, Oligino, Eric, additional, Puc, Matthew, additional, Tregubenko, Polina, additional, Wulff-Burchfield, Elizabeth M., additional, Xie, Zhuoer, additional, Halfdanarson, Thorvardur R., additional, Farmakiotis, Dimitrios, additional, Klein, Elizabeth J., additional, Robilotti, Elizabeth V., additional, Riely, Gregory J., additional, Durand, Jean-Bernard, additional, Hayek, Salim S., additional, Kondapalli, Lavanya, additional, Berg, Stephanie, additional, O'Connor, Timothy E., additional, Bilen, Mehmet A., additional, Castellano, Cecilia, additional, Accordino, Melissa K., additional, Sibel, Blau, additional, Weissmann, Lisa B., additional, Jani, Chinmay, additional, Flora, Daniel B., additional, Rudski, Lawrence, additional, Dutra, Miriam Santos, additional, Nathaniel, Bouganim, additional, Ruíz-García, Erika, additional, Vilar-Compte, Diana, additional, Gupta, Shilpa, additional, Morgans, Alicia, additional, and Nohria, Anju, additional

Published
2023
Full Text
View/download PDF

12. Supplementary Figure from Patients Recently Treated for B-lymphoid Malignancies Show Increased Risk of Severe COVID-19

Author

Rubinstein, Samuel M., primary, Bhutani, Divaya, primary, Lynch, Ryan C., primary, Hsu, Chih-Yuan, primary, Shyr, Yu, primary, Advani, Shailesh, primary, Mesa, Ruben A., primary, Mishra, Sanjay, primary, Mundt, Daniel P., primary, Shah, Dimpy P., primary, Sica, R. Alejandro, primary, Stockerl-Goldstein, Keith E., primary, Stratton, Catherine, primary, Weiss, Matthias, primary, Beeghly-Fadiel, Alicia, primary, Accordino, Melissa, primary, Assouline, Sarit E., primary, Awosika, Joy, primary, Bakouny, Ziad, primary, Bashir, Babar, primary, Berg, Stephanie, primary, Bilen, Mehmet Asim, primary, Castellano, Cecilia A., primary, Cogan, Jacob C., primary, KC, Devendra, primary, Friese, Christopher R., primary, Gupta, Shilpa, primary, Hausrath, Daniel, primary, Hwang, Clara, primary, Johnson, Nathalie A., primary, Joshi, Monika, primary, Kasi, Anup, primary, Klein, Elizabeth J., primary, Koshkin, Vadim S., primary, Kuderer, Nicole M., primary, Kwon, Daniel H., primary, Labaki, Chris, primary, Latif, Tahir, primary, Lau, Eric, primary, Li, Xuanyi, primary, Lyman, Gary H., primary, McKay, Rana R., primary, Nagaraj, Gayathri, primary, Nizam, Amanda, primary, Nonato, Taylor K., primary, Olszewski, Adam J., primary, Polimera, Hyma V., primary, Portuguese, Andrew J., primary, Puc, Matthew M., primary, Razavi, Pedram, primary, Rosovski, Rachel, primary, Schmidt, Andrew, primary, Shah, Sumit A., primary, Shastri, Aditi, primary, Su, Christopher, primary, Torka, Pallawi, primary, Wise-Draper, Trisha M., primary, Zubiri, Leyre, primary, Warner, Jeremy L., primary, and Thompson, Michael A., primary

Published
2023
Full Text
View/download PDF

13. Data from Patients Recently Treated for B-lymphoid Malignancies Show Increased Risk of Severe COVID-19

Author

Rubinstein, Samuel M., primary, Bhutani, Divaya, primary, Lynch, Ryan C., primary, Hsu, Chih-Yuan, primary, Shyr, Yu, primary, Advani, Shailesh, primary, Mesa, Ruben A., primary, Mishra, Sanjay, primary, Mundt, Daniel P., primary, Shah, Dimpy P., primary, Sica, R. Alejandro, primary, Stockerl-Goldstein, Keith E., primary, Stratton, Catherine, primary, Weiss, Matthias, primary, Beeghly-Fadiel, Alicia, primary, Accordino, Melissa, primary, Assouline, Sarit E., primary, Awosika, Joy, primary, Bakouny, Ziad, primary, Bashir, Babar, primary, Berg, Stephanie, primary, Bilen, Mehmet Asim, primary, Castellano, Cecilia A., primary, Cogan, Jacob C., primary, KC, Devendra, primary, Friese, Christopher R., primary, Gupta, Shilpa, primary, Hausrath, Daniel, primary, Hwang, Clara, primary, Johnson, Nathalie A., primary, Joshi, Monika, primary, Kasi, Anup, primary, Klein, Elizabeth J., primary, Koshkin, Vadim S., primary, Kuderer, Nicole M., primary, Kwon, Daniel H., primary, Labaki, Chris, primary, Latif, Tahir, primary, Lau, Eric, primary, Li, Xuanyi, primary, Lyman, Gary H., primary, McKay, Rana R., primary, Nagaraj, Gayathri, primary, Nizam, Amanda, primary, Nonato, Taylor K., primary, Olszewski, Adam J., primary, Polimera, Hyma V., primary, Portuguese, Andrew J., primary, Puc, Matthew M., primary, Razavi, Pedram, primary, Rosovski, Rachel, primary, Schmidt, Andrew, primary, Shah, Sumit A., primary, Shastri, Aditi, primary, Su, Christopher, primary, Torka, Pallawi, primary, Wise-Draper, Trisha M., primary, Zubiri, Leyre, primary, Warner, Jeremy L., primary, and Thompson, Michael A., primary

Published
2023
Full Text
View/download PDF

14. Data from Utilization of COVID-19 Treatments and Clinical Outcomes among Patients with Cancer: A COVID-19 and Cancer Consortium (CCC19) Cohort Study

Author

Rivera, Donna R., primary, Peters, Solange, primary, Panagiotou, Orestis A., primary, Shah, Dimpy P., primary, Kuderer, Nicole M., primary, Hsu, Chih-Yuan, primary, Rubinstein, Samuel M., primary, Lee, Brendan J., primary, Choueiri, Toni K., primary, de Lima Lopes, Gilberto, primary, Grivas, Petros, primary, Painter, Corrie A., primary, Rini, Brian I., primary, Thompson, Michael A., primary, Arcobello, Jonathan, primary, Bakouny, Ziad, primary, Doroshow, Deborah B., primary, Egan, Pamela C., primary, Farmakiotis, Dimitrios, primary, Fecher, Leslie A., primary, Friese, Christopher R., primary, Galsky, Matthew D., primary, Goel, Sanjay, primary, Gupta, Shilpa, primary, Halfdanarson, Thorvardur R., primary, Halmos, Balazs, primary, Hawley, Jessica E., primary, Khaki, Ali Raza, primary, Lemmon, Christopher A., primary, Mishra, Sanjay, primary, Olszewski, Adam J., primary, Pennell, Nathan A., primary, Puc, Matthew M., primary, Revankar, Sanjay G., primary, Schapira, Lidia, primary, Schmidt, Andrew, primary, Schwartz, Gary K., primary, Shah, Sumit A., primary, Wu, Julie T., primary, Xie, Zhuoer, primary, Yeh, Albert C., primary, Zhu, Huili, primary, Shyr, Yu, primary, Lyman, Gary H., primary, and Warner, Jeremy L., primary

Published
2023
Full Text
View/download PDF

15. Supplementary Data from Utilization of COVID-19 Treatments and Clinical Outcomes among Patients with Cancer: A COVID-19 and Cancer Consortium (CCC19) Cohort Study

Author

Rivera, Donna R., primary, Peters, Solange, primary, Panagiotou, Orestis A., primary, Shah, Dimpy P., primary, Kuderer, Nicole M., primary, Hsu, Chih-Yuan, primary, Rubinstein, Samuel M., primary, Lee, Brendan J., primary, Choueiri, Toni K., primary, de Lima Lopes, Gilberto, primary, Grivas, Petros, primary, Painter, Corrie A., primary, Rini, Brian I., primary, Thompson, Michael A., primary, Arcobello, Jonathan, primary, Bakouny, Ziad, primary, Doroshow, Deborah B., primary, Egan, Pamela C., primary, Farmakiotis, Dimitrios, primary, Fecher, Leslie A., primary, Friese, Christopher R., primary, Galsky, Matthew D., primary, Goel, Sanjay, primary, Gupta, Shilpa, primary, Halfdanarson, Thorvardur R., primary, Halmos, Balazs, primary, Hawley, Jessica E., primary, Khaki, Ali Raza, primary, Lemmon, Christopher A., primary, Mishra, Sanjay, primary, Olszewski, Adam J., primary, Pennell, Nathan A., primary, Puc, Matthew M., primary, Revankar, Sanjay G., primary, Schapira, Lidia, primary, Schmidt, Andrew, primary, Schwartz, Gary K., primary, Shah, Sumit A., primary, Wu, Julie T., primary, Xie, Zhuoer, primary, Yeh, Albert C., primary, Zhu, Huili, primary, Shyr, Yu, primary, Lyman, Gary H., primary, and Warner, Jeremy L., primary

Published
2023
Full Text
View/download PDF

16. Systemic Anticancer Therapy and Thromboembolic Outcomes in Hospitalized Patients With Cancer and COVID-19

Author

Gulati, Shuchi, Hsu, Chih-Yuan, Shah, Surbhi, Shah, Pankil K., Zon, Rebecca, Alsamarai, Susan, Awosika, Joy, El-Bakouny, Ziad, Bashir, Babar, Beeghly, Alicia, Berg, Stephanie, de-la-Rosa-Martinez, Daniel, Doroshow, Deborah B., Egan, Pamela C., Fein, Joshua, Flora, Daniel B., Friese, Christopher R., Fromowitz, Ariel, Griffiths, Elizabeth A., Hwang, Clara, Jani, Chinmay, Joshi, Monika, Khan, Hina, Klein, Elizabeth J., Heater, Natalie Knox, Koshkin, Vadim S., Kwon, Daniel H., Labaki, Chris, Latif, Tahir, McKay, Rana R., Nagaraj, Gayathri, Nakasone, Elizabeth S., Nonato, Taylor, Polimera, Hyma V., Puc, Matthew, Razavi, Pedram, Ruiz-Garcia, Erika, Saliby, Renee Maria, Shastri, Aditi, Singh, Sunny R.K., Tagalakis, Vicky, Vilar-Compte, Diana, Weissmann, Lisa B., Wilkins, Cy R., Wise-Draper, Trisha M., Wotman, Michael T., Yoon, James J., Mishra, Sanjay, Grivas, Petros, Shyr, Yu, Warner, Jeremy L., Connors, Jean M., Shah, Dimpy P., Rosovsky, Rachel P., Gulati, Shuchi, Hsu, Chih-Yuan, Shah, Surbhi, Shah, Pankil K., Zon, Rebecca, Alsamarai, Susan, Awosika, Joy, El-Bakouny, Ziad, Bashir, Babar, Beeghly, Alicia, Berg, Stephanie, de-la-Rosa-Martinez, Daniel, Doroshow, Deborah B., Egan, Pamela C., Fein, Joshua, Flora, Daniel B., Friese, Christopher R., Fromowitz, Ariel, Griffiths, Elizabeth A., Hwang, Clara, Jani, Chinmay, Joshi, Monika, Khan, Hina, Klein, Elizabeth J., Heater, Natalie Knox, Koshkin, Vadim S., Kwon, Daniel H., Labaki, Chris, Latif, Tahir, McKay, Rana R., Nagaraj, Gayathri, Nakasone, Elizabeth S., Nonato, Taylor, Polimera, Hyma V., Puc, Matthew, Razavi, Pedram, Ruiz-Garcia, Erika, Saliby, Renee Maria, Shastri, Aditi, Singh, Sunny R.K., Tagalakis, Vicky, Vilar-Compte, Diana, Weissmann, Lisa B., Wilkins, Cy R., Wise-Draper, Trisha M., Wotman, Michael T., Yoon, James J., Mishra, Sanjay, Grivas, Petros, Shyr, Yu, Warner, Jeremy L., Connors, Jean M., Shah, Dimpy P., and Rosovsky, Rachel P.

Abstract

IMPORTANCE: Systematic data on the association between anticancer therapies and thromboembolic events (TEEs) in patients with COVID-19 are lacking. OBJECTIVE: To assess the association between anticancer therapy exposure within 3 months prior to COVID-19 and TEEs following COVID-19 diagnosis in patients with cancer. DESIGN, SETTING, AND PARTICIPANTS: This registry-based retrospective cohort study included patients who were hospitalized and had active cancer and laboratory-confirmed SARS-CoV-2 infection. Data were accrued from March 2020 to December 2021 and analyzed from December 2021 to October 2022. EXPOSURE: Treatments of interest (TOIs) (endocrine therapy, vascular endothelial growth factor inhibitors/tyrosine kinase inhibitors [VEGFis/TKIs], immunomodulators [IMiDs], immune checkpoint inhibitors [ICIs], chemotherapy) vs reference (no systemic therapy) in 3 months prior to COVID-19. MAIN OUTCOMES AND MEASURES: Main outcomes were (1) venous thromboembolism (VTE) and (2) arterial thromboembolism (ATE). Secondary outcome was severity of COVID-19 (rates of intensive care unit admission, mechanical ventilation, 30-day all-cause mortality following TEEs in TOI vs reference group) at 30-day follow-up. RESULTS: Of 4988 hospitalized patients with cancer (median [IQR] age, 69 [59-78] years; 2608 [52%] male), 1869 had received 1 or more TOIs. Incidence of VTE was higher in all TOI groups: endocrine therapy, 7%; VEGFis/TKIs, 10%; IMiDs, 8%; ICIs, 12%; and chemotherapy, 10%, compared with patients not receiving systemic therapies (6%). In multivariable log-binomial regression analyses, relative risk of VTE (adjusted risk ratio [aRR], 1.33; 95% CI, 1.04-1.69) but not ATE (aRR, 0.81; 95% CI, 0.56-1.16) was significantly higher in those exposed to all TOIs pooled together vs those with no exposure. Among individual drugs, ICIs were significantly associated with VTE (aRR, 1.45; 95% CI, 1.01-2.07). Also noted were significant associations between VTE and active and progressing ca

Published
2023

17. COVID-19 Severity and Cardiovascular Outcomes in SARS-CoV-2-Infected Patients With Cancer and Cardiovascular Disease

Author

Moey, Melissa Y.Y., Hennessy, Cassandra, French, Benjamin, Warner, Jeremy L., Tucker, Matthew D., Hausrath, Daniel J., Shah, Dimpy P., DeCara, Jeanne M., Bakouny, Ziad, Labaki, Chris, Choueiri, Toni K., Dent, Susan, Akhter, Nausheen, Ismail-Khan, Roohi, Tachiki, Lisa, Slosky, David, Polonsky, Tamar S., Awosika, Joy A., Crago, Audrey, Wise-Draper, Trisha, Balanchivadze, Nino, Hwang, Clara, Fecher, Leslie A., Gomez, Cyndi Gonzalez, Hayes-Lattin, Brandon, Glover, Michael J., Shah, Sumit A., Gopalakrishnan, Dharmesh, Griffiths, Elizabeth A., Kwon, Daniel H., Koshkin, Vadim S., Mahmood, Sana, Bashir, Babar, Nonato, Taylor, Razavi, Pedram, McKay, Rana R., Nagaraj, Gayathri, Oligino, Eric, Puc, Matthew, Tregubenko, Polina, Wulff-Burchfield, Elizabeth M., Xie, Zhuoer, Halfdanarson, Thorvardur R., Farmakiotis, Dimitrios, Klein, Elizabeth J., Robilotti, Elizabeth V., Riely, Gregory J., Durand, Jean-Bernard, Hayek, Salim S., Kondapalli, Lavanya, Berg, Stephanie, O'Connor, Timothy E., Bilen, Mehmet A., Castellano, Cecilia, Accordino, Melissa K., Sibel, Blau, Weissmann, Lisa B., Jani, Chinmay, Flora, Daniel B., Rudski, Lawrence, Dutra, Miriam Santos, Nathaniel, Bouganim, Ruíz-García, Erika, Vilar-Compte, Diana, Gupta, Shilpa, Morgans, Alicia, Nohria, Anju, Moey, Melissa Y.Y., Hennessy, Cassandra, French, Benjamin, Warner, Jeremy L., Tucker, Matthew D., Hausrath, Daniel J., Shah, Dimpy P., DeCara, Jeanne M., Bakouny, Ziad, Labaki, Chris, Choueiri, Toni K., Dent, Susan, Akhter, Nausheen, Ismail-Khan, Roohi, Tachiki, Lisa, Slosky, David, Polonsky, Tamar S., Awosika, Joy A., Crago, Audrey, Wise-Draper, Trisha, Balanchivadze, Nino, Hwang, Clara, Fecher, Leslie A., Gomez, Cyndi Gonzalez, Hayes-Lattin, Brandon, Glover, Michael J., Shah, Sumit A., Gopalakrishnan, Dharmesh, Griffiths, Elizabeth A., Kwon, Daniel H., Koshkin, Vadim S., Mahmood, Sana, Bashir, Babar, Nonato, Taylor, Razavi, Pedram, McKay, Rana R., Nagaraj, Gayathri, Oligino, Eric, Puc, Matthew, Tregubenko, Polina, Wulff-Burchfield, Elizabeth M., Xie, Zhuoer, Halfdanarson, Thorvardur R., Farmakiotis, Dimitrios, Klein, Elizabeth J., Robilotti, Elizabeth V., Riely, Gregory J., Durand, Jean-Bernard, Hayek, Salim S., Kondapalli, Lavanya, Berg, Stephanie, O'Connor, Timothy E., Bilen, Mehmet A., Castellano, Cecilia, Accordino, Melissa K., Sibel, Blau, Weissmann, Lisa B., Jani, Chinmay, Flora, Daniel B., Rudski, Lawrence, Dutra, Miriam Santos, Nathaniel, Bouganim, Ruíz-García, Erika, Vilar-Compte, Diana, Gupta, Shilpa, Morgans, Alicia, and Nohria, Anju

Abstract

BACKGROUND: Data regarding outcomes among patients with cancer and co-morbid cardiovascular disease (CVD)/cardiovascular risk factors (CVRF) after SARS-CoV-2 infection are limited. OBJECTIVES: To compare Coronavirus disease 2019 (COVID-19) related complications among cancer patients with and without co-morbid CVD/CVRF. METHODS: Retrospective cohort study of patients with cancer and laboratory-confirmed SARS-CoV-2, reported to the COVID-19 and Cancer Consortium (CCC19) registry from 03/17/2020 to 12/31/2021. CVD/CVRF was defined as established CVD RESULTS: Among 10,876 SARS-CoV-2 infected patients with cancer (median age 65 [IQR 54-74] years, 53% female, 52% White), 6253 patients (57%) had co-morbid CVD/CVRF. Co-morbid CVD/CVRF was associated with higher COVID-19 severity (adjusted OR: 1.25 [95% CI 1.11-1.40]). Adverse CV events were significantly higher in patients with CVD/CVRF (all CONCLUSIONS: Co-morbid CVD/CVRF is associated with higher COVID-19 severity among patients with cancer, particularly those not receiving active cancer therapy. While infrequent, COVID-19 related CV complications were higher in patients with comorbid CVD/CVRF. (COVID-19 and Cancer Consortium Registry [CCC19]; NCT04354701).

Published
2023

18. Clinical Characteristics, Racial Inequities, and Outcomes in Patients with Breast Cancer and COVID-19: A COVID-19 and Cancer Consortium (CCC19) Cohort Study

Author

Nagaraj, Gayathri, primary, Vinayak, Shaveta, additional, Khaki, Ali Raza, additional, Sun, Tianyi, additional, Kuderer, Nicole M., additional, Aboulafia, David M., additional, Acoba, Jared D., additional, Awosika, Joy, additional, Bakouny, Ziad, additional, Balmaceda, Nicole B., additional, Bao, Ting, additional, Bashir, Babar, additional, Berg, Stephanie, additional, Bilen, Mehmet A., additional, Bindal, Poorva, additional, Blau, Sibel, additional, Bodin, Brianne E., additional, Borno, Hala T., additional, Castellano, Cecilia, additional, Choi, Horyun, additional, Deeken, John, additional, Desai, Aakash, additional, Edwin, Natasha, additional, Feldman, Lawrence E., additional, Flora, Daniel B., additional, Friese, Christopher R., additional, Galsky, Matthew D., additional, Gonzalez, Cyndi J., additional, Grivas, Petros, additional, Gupta, Shilpa, additional, Haynam, Marcy, additional, Heilman, Hannah, additional, Hershman, Dawn L., additional, Hwang, Clara, additional, Jani, Chinmay, additional, Jhawar, Sachin R., additional, Joshi, Monika, additional, Kaklamani, Virginia, additional, Klein, Elizabeth J., additional, Knox, Natalie, additional, Koshkin, Vadim S., additional, Kulkarni, Amit A., additional, Kwon, Daniel H., additional, Labaki, Chris, additional, Lammers, Philip E., additional, Lathrop, Kate I., additional, Lewis, Mark A., additional, Li, Xuanyi, additional, de Lima Lopes, Gilberto, additional, Lyman, Gary H., additional, Makower, Della F., additional, Mansoor, Abdul-Hai, additional, Markham, Merry-Jennifer, additional, Mashru, Sandeep H., additional, McKay, Rana R., additional, Messing, Ian, additional, Mico, Vasil, additional, Nadkarni, Rajani, additional, Namburi, Swathi, additional, Nguyen, Ryan H., additional, Nonato, Taylor Kristian, additional, O’Connor, Tracey Lynn, additional, Panagiotou, Orestis A., additional, Park, Kyu, additional, Patel, Jaymin M., additional, Patel, Kanishka GopikaBimal, additional, Peppercorn, Jeffrey, additional, Polimera, Hyma, additional, Puc, Matthew, additional, Rao, Yuan James, additional, Razavi, Pedram, additional, Reid, Sonya A., additional, Riess, Jonathan W., additional, Rivera, Donna R., additional, Robson, Mark, additional, Rose, Suzanne J., additional, Russ, Atlantis D., additional, Schapira, Lidia, additional, Shah, Pankil K., additional, Shanahan, M. Kelly, additional, Shapiro, Lauren C., additional, Smits, Melissa, additional, Stover, Daniel G., additional, Streckfuss, Mitrianna, additional, Tachiki, Lisa, additional, Thompson, Michael A., additional, Tolaney, Sara M., additional, Weissmann, Lisa B., additional, Wilson, Grace, additional, Wotman, Michael T., additional, Wulff-Burchfield, Elizabeth M., additional, Mishra, Sanjay, additional, French, Benjamin, additional, Warner, Jeremy L., additional, Lustberg, Maryam B., additional, Accordino, Melissa K., additional, and Shah, Dimpy P., additional

Published
2023
Full Text
View/download PDF

19. Additional file 1 of Impact of COVID-19 in patients on active melanoma therapy and with history of melanoma

Author

Johnson, Douglas B., Atkins, Michael B., Hennessy, Cassandra, Wise-Draper, Trisha, Heilman, Hannah, Awosika, Joy, Bakouny, Ziad, Labaki, Chris, Saliby, Renee Maria, Hwang, Clara, Singh, Sunny R. K., Balanchivadze, Nino, Friese, Christopher R., Fecher, Leslie A., Yoon, James J., Hayes-Lattin, Brandon, Bilen, Mehmet A., Castellano, Cecilia A., Lyman, Gary H., Tachiki, Lisa, Shah, Sumit A., Glover, Michael J., Flora, Daniel B., Wulff-Burchfield, Elizabeth, Kasi, Anup, Abbasi, Saqib H., Farmakiotis, Dimitrios, Viera, Kendra, Klein, Elizabeth J., Weissman, Lisa B., Jani, Chinmay, Puc, Matthew, Fahey, Catherine C., Reuben, Daniel Y., Mishra, Sanjay, Beeghly-Fadiel, Alicia, French, Benjamin, and Warner, Jeremy L.

Abstract

Additional file 1: Supplemental Table 1. Outcomes summarized over full patient cohort. Supplementary Table 2. Organ function in hospitalized patients based on therapy type. Supplemental Table 3. Survival in patients without active cancer or treatment in the previous 3 months.

Published
2023
Full Text
View/download PDF

20. Patients Recently Treated for B-lymphoid Malignancies Show Increased Risk of Severe COVID-19

Author

Rubinstein, Samuel M, Bhutani, Divaya, Lynch, Ryan C, Hsu, Chih-Yuan, Shyr, Yu, Advani, Shailesh, Mesa, Ruben A, Mishra, Sanjay, Mundt, Daniel P, Shah, Dimpy P, Sica, R Alejandro, Stockerl-Goldstein, Keith E, Stratton, Catherine, Weiss, Matthias, Beeghly-Fadiel, Alicia, Accordino, Melissa, Assouline, Sarit E, Awosika, Joy, Bakouny, Ziad, Bashir, Babar, Berg, Stephanie, Bilen, Mehmet Asim, Castellano, Cecilia A, Cogan, Jacob C, Kc, Devendra, Friese, Christopher R, Gupta, Shilpa, Hausrath, Daniel, Hwang, Clara, Johnson, Nathalie A, Joshi, Monika, Kasi, Anup, Klein, Elizabeth J, Koshkin, Vadim S, Kuderer, Nicole M, Kwon, Daniel H, Labaki, Chris, Latif, Tahir, Lau, Eric, Li, Xuanyi, Lyman, Gary H, McKay, Rana R, Nagaraj, Gayathri, Nizam, Amanda, Nonato, Taylor K, Olszewski, Adam J, Polimera, Hyma V, Portuguese, Andrew J, Puc, Matthew M, Razavi, Pedram, Rosovski, Rachel, Schmidt, Andrew, Shah, Sumit A, Shastri, Aditi, Su, Christopher, Torka, Pallawi, Wise-Draper, Trisha M, Zubiri, Leyre, Warner, Jeremy L, Thompson, Michael A, and COVID-19 and Cancer Consortium

Subjects
SARS-CoV-2, Prevention, COVID-19, COVID-19 Testing, Rare Diseases, COVID-19 and Cancer Consortium, Risk Factors, Clinical Research, Neoplasms, Humans, 2.1 Biological and endogenous factors, Aetiology, Lymphatic Diseases, Cancer
Abstract

Patients with B-lymphoid malignancies have been consistently identified as a population at high risk of severe COVID-19. Whether this is exclusively due to cancer-related deficits in humoral and cellular immunity, or whether risk of severe COVID-19 is increased by anticancer therapy, is uncertain. Using data derived from the COVID-19 and Cancer Consortium (CCC19), we show that patients treated for B-lymphoid malignancies have an increased risk of severe COVID-19 compared with control populations of patients with non-B-lymphoid malignancies. Among patients with B-lymphoid malignancies, those who received anticancer therapy within 12 months of COVID-19 diagnosis experienced increased COVID-19 severity compared with patients with non-recently treated B-lymphoid malignancies, after adjustment for cancer status and several other prognostic factors. Our findings suggest that patients recently treated for a B-lymphoid malignancy are at uniquely high risk for severe COVID-19.SignificanceOur study suggests that recent therapy for a B-lymphoid malignancy is an independent risk factor for COVID-19 severity. These findings provide rationale to develop mitigation strategies targeted at the uniquely high-risk population of patients with recently treated B-lymphoid malignancies. This article is highlighted in the In This Issue feature, p. 171.

Published
2022

21. Assessment of Regional Variability in COVID-19 Outcomes Among Patients With Cancer in the United States.

Author

Hawley, Jessica E, Sun, Tianyi, Chism, David D, Duma, Narjust, Fu, Julie C, Gatson, Na Tosha N, Mishra, Sanjay, Nguyen, Ryan H, Reid, Sonya A, Serrano, Oscar K, Singh, Sunny R K, Venepalli, Neeta K, Bakouny, Ziad, Bashir, Babar, Bilen, Mehmet A, Caimi, Paolo F, Choueiri, Toni K, Dawsey, Scott J, Fecher, Leslie A, Flora, Daniel B, Friese, Christopher R, Glover, Michael J, Gonzalez, Cyndi J, Goyal, Sharad, Halfdanarson, Thorvardur R, Hershman, Dawn L, Khan, Hina, Labaki, Chris, Lewis, Mark A, McKay, Rana R, Messing, Ian, Pennell, Nathan A, Puc, Matthew, Ravindranathan, Deepak, Rhodes, Terence D, Rivera, Andrea V, Roller, John, Schwartz, Gary K, Shah, Sumit A, Shaya, Justin A, Streckfuss, Mitrianna, Thompson, Michael A, Wulff-Burchfield, Elizabeth M, Xie, Zhuoer, Yu, Peter Paul, Warner, Jeremy L, Shah, Dimpy P, French, Benjamin, Hwang, Clara, Hawley, Jessica E, Sun, Tianyi, Chism, David D, Duma, Narjust, Fu, Julie C, Gatson, Na Tosha N, Mishra, Sanjay, Nguyen, Ryan H, Reid, Sonya A, Serrano, Oscar K, Singh, Sunny R K, Venepalli, Neeta K, Bakouny, Ziad, Bashir, Babar, Bilen, Mehmet A, Caimi, Paolo F, Choueiri, Toni K, Dawsey, Scott J, Fecher, Leslie A, Flora, Daniel B, Friese, Christopher R, Glover, Michael J, Gonzalez, Cyndi J, Goyal, Sharad, Halfdanarson, Thorvardur R, Hershman, Dawn L, Khan, Hina, Labaki, Chris, Lewis, Mark A, McKay, Rana R, Messing, Ian, Pennell, Nathan A, Puc, Matthew, Ravindranathan, Deepak, Rhodes, Terence D, Rivera, Andrea V, Roller, John, Schwartz, Gary K, Shah, Sumit A, Shaya, Justin A, Streckfuss, Mitrianna, Thompson, Michael A, Wulff-Burchfield, Elizabeth M, Xie, Zhuoer, Yu, Peter Paul, Warner, Jeremy L, Shah, Dimpy P, French, Benjamin, and Hwang, Clara

Abstract

Importance: The COVID-19 pandemic has had a distinct spatiotemporal pattern in the United States. Patients with cancer are at higher risk of severe complications from COVID-19, but it is not well known whether COVID-19 outcomes in this patient population were associated with geography. Objective: To quantify spatiotemporal variation in COVID-19 outcomes among patients with cancer. Design, Setting, and Participants: This registry-based retrospective cohort study included patients with a historical diagnosis of invasive malignant neoplasm and laboratory-confirmed SARS-CoV-2 infection between March and November 2020. Data were collected from cancer care delivery centers in the United States. Exposures: Patient residence was categorized into 9 US census divisions. Cancer center characteristics included academic or community classification, rural-urban continuum code (RUCC), and social vulnerability index. Main Outcomes and Measures: The primary outcome was 30-day all-cause mortality. The secondary composite outcome consisted of receipt of mechanical ventilation, intensive care unit admission, and all-cause death. Multilevel mixed-effects models estimated associations of center-level and census division-level exposures with outcomes after adjustment for patient-level risk factors and quantified variation in adjusted outcomes across centers, census divisions, and calendar time. Results: Data for 4749 patients (median [IQR] age, 66 [56-76] years; 2439 [51.4%] female individuals, 1079 [22.7%] non-Hispanic Black individuals, and 690 [14.5%] Hispanic individuals) were reported from 83 centers in the Northeast (1564 patients [32.9%]), Midwest (1638 [34.5%]), South (894 [18.8%]), and West (653 [13.8%]). After adjustment for patient characteristics, including month of COVID-19 diagnosis, estimated 30-day mortality rates ranged from 5.2% to 26.6% across centers. Patients from centers located in metropolitan areas with population less than 250 000 (RUCC 3) had lower odds of 30-day

Published
2022

22. Surface Modifications of Mechanical Heart Valves : Effects on Thrombogenicity

Author

Tran, Hoang S., Puc, Matthew M., Chrzanowski, Frank A., Jr., Hewitt, Charles W., Soll, David B., Singh, Bawa, Kumar, Nalin, Marra, Steven, Simonetti, Vincent, Cilley, Jonathan, DelRossi, Anthony J., Wise, Donald L., editor, Gresser, Joseph D., editor, Trantolo, Debra J., editor, Cattaneo, Mario V., editor, Lewandrowski, Kai-Uwe, editor, and Yaszemski, Michael J., editor

Published
2000
Full Text
View/download PDF

23. Breakthrough SARS-CoV-2 Infections Among Patients with Cancer Following Two and Three Doses of COVID-19 mRNA Vaccines

Author

Choueiri, Toni K., primary, Labaki, Chris, additional, Bakouny, Ziad, additional, Hsu, Chih-Yuan, additional, Schmidt, Andrew L., additional, de Lima Lopes, Gilberto, additional, Hwang, Clara, additional, Singh, Sunny R.K., additional, Jani, Chinmay, additional, Weissmann, Lisa B., additional, Griffiths, Elizabeth A., additional, Halabi, Susan, additional, Wu, Ulysses, additional, Berg, Stephanie, additional, O’Connor, Timothy E., additional, Wise-Draper, Trisha M., additional, Panagiotou, Orestis A., additional, Klein, Elizabeth J., additional, Joshi, Monika, additional, Dutra, Miriam Santos, additional, Gatson, Na Tosha N., additional, Blau, Sibel, additional, Singh, Harpreet, additional, Nanchal, Rahul, additional, McKay, Rana R., additional, Nonato, Taylor K., additional, Quinn, Ryann, additional, Rubinstein, Samuel M., additional, Puc, Matthew, additional, Mavromatis, Blanche H., additional, Vikas, Praveen, additional, Faller, Bryan, additional, Zaren, Howard A., additional, Del Prete, Salvatore, additional, Russell, Karen, additional, Reuben, Daniel Y., additional, Accordino, Melissa, additional, Friese, Christopher R., additional, Mishra, Sanjay, additional, Rivera, Donna R., additional, Shyr, Yu, additional, Farmakiotis, Dimitrios, additional, and Warner, Jeremy L., additional

Published
2022
Full Text
View/download PDF

24. Bleeding Complications in Patients with Cancer and COVID 19- Analysis from the COVID 19and Cancer Consortium (CCC19) Registry

Author

Shah, Surbhi, primary, Gulati, Shuchi, additional, Li, Ang, additional, Fu, Julie, additional, Kumar, Vaibhav, additional, Zon, Rebecca, additional, Kulkarni, Amit, additional, Shah, Pankil, additional, Byeff, Peter D., additional, Nguyen, Ryan, additional, Nagaraj, Gayathri, additional, Puc, Matthew, additional, Hwang, Clara, additional, McKay, Rana, additional, French, Benjamin, additional, Hennessy, Cassandra, additional, Warner, Jeremy L., additional, Connors, Jean M., additional, Shah, Dimpy P., additional, and Rosovsky, Rachel P., additional

Published
2021
Full Text
View/download PDF

25. Interplay of Immunosuppression and Immunotherapy Among Patients With Cancer and COVID-19

Author

Bakouny, Ziad, Labaki, Chris, Grover, Punita, Awosika, Joy, Gulati, Shuchi, Hsu, Chih-Yuan, Alimohamed, Saif I., Bashir, Babar, Berg, Stephanie, Bilen, Mehmet A., Bowles, Daniel, Castellano, Cecilia, Desai, Aakash, Elkrief, Arielle, Eton, Omar E., Fecher, Leslie A., Flora, Daniel, Galsky, Matthew D., Gatti-Mays, Margaret E., Gesenhues, Alicia, Glover, Michael J., Gopalakrishnan, Dharmesh, Gupta, Shilpa, Halfdanarson, Thorvardur R., Hayes-Lattin, Brandon, Hendawi, Mohamed, Hsu, Emily, Hwang, Clara, Jandarov, Roman, Jani, Chinmay, Johnson, Douglas B., Joshi, Monika, Khan, Hina, Khan, Shaheer A., Knox, Natalie, Koshkin, Vadim S., Kulkarni, Amit A., Kwon, Daniel H., Matar, Sara, McKay, Rana R., Mishra, Sanjay, Moria, Feras A., Nizam, Amanda, Nock, Nora L., Nonato, Taylor K., Panasci, Justin, Pomerantz, Lauren, Portuguese, Andrew J., Provenzano, Destie, Puc, Matthew, Rao, Yuan J., Rhodes, Terence D., Riely, Gregory J., Ripp, Jacob J., Rivera, Andrea V., Ruiz-Garcia, Erika, Schmidt, Andrew L., Schoenfeld, Adam J., Schwartz, Gary K., Shah, Sumit A., Shaya, Justin, Subbiah, Suki, Tachiki, Lisa M., Tucker, Matthew D., Valdez-Reyes, Melissa, Weissmann, Lisa B., Wotman, Michael T., Wulff-Burchfield, Elizabeth M., Xie, Zhuoer, Yang, Yuanchu James, Thompson, Michael A., Shah, Dimpy P., Warner, Jeremy L., Shyr, Yu, Choueiri, Toni K., and Wise-Draper, Trisha M.

Abstract

IMPORTANCE: Cytokine storm due to COVID-19 can cause high morbidity and mortality and may be more common in patients with cancer treated with immunotherapy (IO) due to immune system activation. OBJECTIVE: To determine the association of baseline immunosuppression and/or IO-based therapies with COVID-19 severity and cytokine storm in patients with cancer. DESIGN, SETTING, AND PARTICIPANTS: This registry-based retrospective cohort study included 12 046 patients reported to the COVID-19 and Cancer Consortium (CCC19) registry from March 2020 to May 2022. The CCC19 registry is a centralized international multi-institutional registry of patients with COVID-19 with a current or past diagnosis of cancer. Records analyzed included patients with active or previous cancer who had a laboratory-confirmed infection with SARS-CoV-2 by polymerase chain reaction and/or serologic findings. EXPOSURES: Immunosuppression due to therapy; systemic anticancer therapy (IO or non-IO). MAIN OUTCOMES AND MEASURES: The primary outcome was a 5-level ordinal scale of COVID-19 severity: no complications; hospitalized without requiring oxygen; hospitalized and required oxygen; intensive care unit admission and/or mechanical ventilation; death. The secondary outcome was the occurrence of cytokine storm. RESULTS: The median age of the entire cohort was 65 years (interquartile range [IQR], 54-74) years and 6359 patients were female (52.8%) and 6598 (54.8%) were non-Hispanic White. A total of 599 (5.0%) patients received IO, whereas 4327 (35.9%) received non-IO systemic anticancer therapies, and 7120 (59.1%) did not receive any antineoplastic regimen within 3 months prior to COVID-19 diagnosis. Although no difference in COVID-19 severity and cytokine storm was found in the IO group compared with the untreated group in the total cohort (adjusted odds ratio [aOR], 0.80; 95% CI, 0.56-1.13, and aOR, 0.89; 95% CI, 0.41-1.93, respectively), patients with baseline immunosuppression treated with IO (vs untreated) had worse COVID-19 severity and cytokine storm (aOR, 3.33; 95% CI, 1.38-8.01, and aOR, 4.41; 95% CI, 1.71-11.38, respectively). Patients with immunosuppression receiving non-IO therapies (vs untreated) also had worse COVID-19 severity (aOR, 1.79; 95% CI, 1.36-2.35) and cytokine storm (aOR, 2.32; 95% CI, 1.42-3.79). CONCLUSIONS AND RELEVANCE: This cohort study found that in patients with cancer and COVID-19, administration of systemic anticancer therapies, especially IO, in the context of baseline immunosuppression was associated with severe clinical outcomes and the development of cytokine storm. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT04354701

Published
2023
Full Text
View/download PDF

26. Lower respiratory tract disease (LRTD) in patients with cancer and COVID-19: A COVID-19 and Cancer Consortium (CCC19) study.

Author

Shah, Dimpy P, primary, Shah, Pankil, additional, Schmidt, Andrew Lachlan, additional, Bakouny, Ziad, additional, Farmakiotis, Dimitrios, additional, Abidi, Maheen, additional, Rubinstein, Samuel M., additional, Figueroa, Cesar J., additional, Labaki, Chris, additional, Friese, Christopher Ryan, additional, Rathmann, Joerg, additional, Hwang, Clara, additional, McKay, Rana R., additional, Park, Cathleen, additional, Puc, Matthew, additional, Nagaraj, Gayathri, additional, French, Benjamin, additional, Warner, Jeremy Lyle, additional, and Shete, Sanjay, additional

Published
2021
Full Text
View/download PDF

27. Concomitant infections in patients with cancer and COVID-19: A COVID-19 and Cancer Consortium (CCC19) study.

Author

Enriquez, Kyle T., primary, Satyanarayana, Gowri, additional, Abidi, Maheen, additional, Advani, Shailesh M, additional, Egan, Pamela, additional, Elkrief, Arielle, additional, French, Benjamin, additional, Friese, Christopher Ryan, additional, Hwang, Clara, additional, Khan, Hina, additional, Lyman, Gary H., additional, McKay, Rana R., additional, Nagaraj, Gayathri, additional, Puc, Matthew, additional, Robilotti, Elizabeth M, additional, Gupta, Shilpa, additional, Shah, Dimpy P, additional, Wise-Draper, Trisha Michel, additional, Yu, Peter Paul, additional, and Farmakiotis, Dimitrios, additional

Published
2021
Full Text
View/download PDF

28. Racial and ethnic disparities among patients with breast cancer and COVID-19.

Author

Nagaraj, Gayathri, primary, Accordino, Melissa Kate, additional, French, Benjamin, additional, Kuderer, Nicole M., additional, Lyman, Gary H., additional, Stover, Daniel G., additional, Blinder, Victoria Susana, additional, Schmidt, Andrew Lachlan, additional, Shatsky, Rebecca Arielle, additional, Grover, Punita, additional, Puc, Matthew, additional, Hwang, Clara, additional, Wulff-Burchfield, Elizabeth Marie, additional, Lewis, Mark Andrew, additional, Menendez, Alvaro G., additional, Bilen, Mehmet Asim, additional, Warner, Jeremy Lyle, additional, Lustberg, Maryam B., additional, and Shah, Dimpy P, additional

Published
2021
Full Text
View/download PDF

29. Code status and outcomes in patients with cancer and COVID-19: A COVID-19 and cancer consortium (CCC19) registry analysis.

Author

Loggers, Elizabeth Trice, primary, Wulff-Burchfield, Elizabeth Marie, additional, Subbiah, Ishwaria Mohan, additional, Khaki, Ali Raza, additional, Egan, Pamela, additional, Farmakiotis, Dimitrios, additional, Phull, Hardeep, additional, Nakasone, Elizabeth, additional, Labaki, Chris, additional, Yu, Peter Paul, additional, Joshi, Monika, additional, Griffiths, Elizabeth A., additional, Wise-Draper, Trisha Michel, additional, Jani, Chinmay, additional, Thakkar, Astha, additional, Puc, Matthew, additional, Hwang, Clara, additional, Mavromatis, Blanche H., additional, Shah, Dimpy P, additional, and Warner, Jeremy Lyle, additional

Published
2021
Full Text
View/download PDF

31. A Systematic Framework to Rapidly Obtain Data on Patients with Cancer and COVID-19: CCC19 Governance, Protocol, and Quality Assurance

Author

Abidi, Maheen, primary, Aboulafia, David M., additional, Accordino, Melissa K., additional, Acoba, Jared D., additional, Ahluwalia, Manmeet S., additional, Ahmad, Syed A., additional, Ajmera, Archana, additional, Alimohamed, Saif I., additional, Altman, Jessica, additional, Angevine, Anne H., additional, Bakouny, Ziad, additional, Bar, Michael H., additional, Bardia, Aditya, additional, Barnholtz-Sloan, Jill S., additional, Barrow McCollough, Briana, additional, Bashir, Babar, additional, Batist, Gerald, additional, Bekaii-Saab, Tanios S., additional, Berg, Stephanie, additional, Bernicker, Eric H., additional, Bhutani, Divaya, additional, Bilen, Mehmet A., additional, Bindal, Poorva, additional, Bishnoi, Rohit, additional, Blau, Sibel, additional, Bohachek, Pamela, additional, Boland, Genevieve, additional, Bonnen, Mark, additional, Bouchard, Gabrielle, additional, Bouganim, Nathaniel, additional, Bowles, Daniel W., additional, Busser, Fiona J., additional, Butt, Omar, additional, Cabal, Angelo, additional, Cabalona, Wilhelmina D., additional, Cabebe, Elwyn C., additional, Caimi, Paolo, additional, Campian, Jian L., additional, Carducci, Theresa M., additional, Chen, James L., additional, Cheng, Alex, additional, Chism, David D., additional, Choueiri, Toni K., additional, Clark, Melanie J., additional, Clement, Jessica M., additional, Connors, Jean M., additional, Cook, Erin, additional, Curran, Catherine R., additional, Daher, Ahmad, additional, Dailey, Mark E., additional, Davis, Elizabeth J., additional, Dawsey, Scott J., additional, Deeken, John F., additional, Del Prete, Salvatore A., additional, Demetri, George D., additional, Desai, Aakash, additional, Doroshow, Deborah B., additional, Durbin, Eric B., additional, Egan, Pamela C., additional, Elias, Rawad, additional, Elkrief, Arielle, additional, Elms, Destry J., additional, Elshoury, Amro, additional, Faller, Bryan, additional, Farmakiotis, Dimitrios, additional, Fecher, Leslie A., additional, Feldman, Lawrence E., additional, Ferrario, Cristiano, additional, Fiala, Mark A., additional, Flora, Daniel B., additional, French, Benjamin, additional, Friese, Christopher R., additional, Fu, Julie C., additional, Gadgeel, Shirish M., additional, Gainor, Justin, additional, Galsky, Matthew D., additional, Gantt, Gerald, additional, Garcia, Jorge A., additional, Gartrell, Benjamin A., additional, Gatti-Mays, Margaret E., additional, Gill, David M., additional, Gillaspie, Erin A., additional, Giordano, Antonio, additional, Glace, (Mary) Grace, additional, Glover, Michael J., additional, Goel, Sanjay, additional, Graber, Jerome J., additional, Griffiths, Elizabeth A., additional, Grivas, Petros, additional, Grover, Punita, additional, Gulati, Anthony P., additional, Gulati, Shuchi, additional, Gupta, Shilpa, additional, Gurley, Michael, additional, Hafez, Navid, additional, Halabi, Susan, additional, Halfdanarson, Thorvardur R., additional, Halmos, Balazs, additional, Hausrath, Daniel J., additional, Hawley, Jessica E., additional, Hennessy, Cassandra, additional, Herbst, Roy S., additional, Hershman, Dawn L., additional, Hoppenot, Claire, additional, Hoskins, Kent F., additional, Hoyo-Ulloa, Irma, additional, Hsu, Emily, additional, Hsu, Chih-Yuan, additional, Hwang, Clara, additional, Islam, Jessica Yasmine, additional, Jabbour, Salma K., additional, Jani, Chinmay, additional, Jha, Alokkumar, additional, Jhawar, Sachin R., additional, Johnson, Douglas B., additional, Joshi, Monika, additional, Kasi, Anup, additional, Kelleher, Kaitlin, additional, Kennecke, Hagen F., additional, Khaki, Ali Raza, additional, Khan, Hina, additional, Khan, Mahir, additional, Kharofa, Jordan, additional, Kloecker, Goetz, additional, Knoble, Jeanna L., additional, Kulkarni, Amit A., additional, Kumar, Vaibhav, additional, Lammers, Philip E., additional, Leighton, John C., additional, Lemmon, Christopher A., additional, Lewis, Mark A., additional, Li, Ang, additional, Li, Xuanyi, additional, Liu, Stephen V., additional, Lo, K.M., additional, Loaiza-Bonilla, Arturo, additional, Logan, Barbara B., additional, Loggers, Elizabeth T., additional, de Lima Lopes, Gilberto, additional, Loree, Jonathan M., additional, LoRusso, Patricia, additional, Low, Clarke A., additional, Lustberg, Maryam B., additional, Lyman, Gary H., additional, Lynch, Ryan C., additional, Madhavan, Subha, additional, Mahadevan, Daruka, additional, Mahmood, Sana Z., additional, Mansoor, Abdul-Hai, additional, Marcum, Michelle, additional, Markham, Merry-Jennifer, additional, Mashru, Sandeep H., additional, Masters, Tyler, additional, Mavromatis, Blanche H., additional, McKay, Rana R., additional, McNair, Christopher, additional, McWeeney, Shannon, additional, Menendez, Alvaro G., additional, Menon, Harry, additional, Mesa, Ruben A., additional, Mico, Vasil, additional, Miller, Chaim, additional, Mishra, Sanjay, additional, Monahan, Ryan S., additional, Morgans, Alicia K., additional, Mulcahy, Mary F., additional, Mundt, Daniel, additional, Mushtaq, Sarah, additional, Nagaraj, Gayathri, additional, Nagle, Sarah, additional, Nakasone, Elizabeth S., additional, Nakayama, John M., additional, Nelson, Heather H., additional, Nemecek, Eneida R., additional, Nguyen, Ryan H., additional, Nizam, Amanda, additional, Nohria, Anju, additional, Nuzzo, Pier Vitale, additional, Ohri, Nitin, additional, Olszewski, Adam J., additional, Owenby, Susie, additional, Painter, Corrie A., additional, Palmer, Joshua D., additional, Panagiotou, Orestis A., additional, Park, Cathleen, additional, Pasquinelli, Mary M., additional, Patel, Jaymin M., additional, Patel, Kanishka G., additional, Peddi, Prakash, additional, Pennell, Nathan A., additional, Peters, Solange, additional, Pilar, Christine, additional, Pillainayagam, Clement, additional, Puc, Matthew, additional, Ramirez, Amelie G., additional, Rathmann, Joerg, additional, Ravindranathan, Deepak, additional, Reid, Sonya A., additional, Reuben, Daniel Y., additional, Revankar, Sanjay G., additional, Reynolds, Kerry L., additional, Rho, Young Soo, additional, Rhodes, Terence D., additional, Rice, Robert L., additional, Riess, Jonathan, additional, Rini, Brian I., additional, Rink, Cameron, additional, Rosen, Lane R., additional, Rosenstein, Lori J., additional, Rosovsky, Rachel P., additional, Routy, Bertrand, additional, Rovito, Marc A., additional, Rubinstein, Samuel M., additional, Saif, M. Wasif, additional, Salazar, Mary, additional, Santos Dutra, Miriam, additional, Schapira, Lidia, additional, Schmidt, Andrew L., additional, Schroeder, Brett A., additional, Schwartz, Gary K., additional, Schwartz, Candice, additional, Schweizer, Michael T., additional, Serrano, Oscar K., additional, Shafer, Danielle A., additional, Shah, Pankil K., additional, Shah, Dimpy, additional, Shah, Mansi R., additional, Shah, Sumit A., additional, Shah, Chintan, additional, Shaw, Grace, additional, Shaya, Justin A., additional, Shyr, Yu, additional, Slosky, David A., additional, Smits, Melissa, additional, Solorzano, Carmen C., additional, Stauffer, Karen, additional, Stockerl-Goldstein, Keith E., additional, Stover, Daniel G., additional, Stratton, Jamie, additional, Stratton, Catherine, additional, Streckfuss, Mitrianna, additional, Subbiah, Suki, additional, Tachiki, Lisa, additional, Tadesse, Eyob, additional, Thompson, Michael A., additional, Topaloglu, Umit, additional, Tucker, Matthew D., additional, Van Allen, Eliezer M., additional, Van Loon, Susan, additional, Vega-Luna, Karen, additional, Venepalli, Neeta K., additional, Verma, Amit, additional, Vikas, Praveen, additional, Vinayak, Shaveta, additional, Vinh, Donald C., additional, Wagner, Michael J., additional, Wall, Sarah, additional, Wang, Lucy L., additional, Warner, Jeremy L., additional, Wehbe, Firas H., additional, Weinstein, Paul L., additional, Weiss, Matthias, additional, Weissmann, Lisa B., additional, Wildes, Tanya M., additional, Williams, Nicole, additional, Wise-Draper, Trisha M., additional, Wood, William A., additional, Wu, Julie Tsu-Yu, additional, Wulff-Burchfield, Elizabeth M., additional, Xie, Zhuoer, additional, Xu, Wenxin, additional, Yeh, Albert C., additional, Yu, Irene S., additional, Yu, Peter Paul, additional, Zacks, Rosemary, additional, Zaman, Qamar Ul, additional, Zaren, Howard, additional, Zhang, Tian, additional, Zhou, Alice Y., additional, Zhu, Huili, additional, Zon, Rebecca L., additional, and Zubiri, Leyre, additional

Published
2020
Full Text
View/download PDF

32. Utilization of COVID-19 Treatments and Clinical Outcomes among Patients with Cancer: A COVID-19 and Cancer Consortium (CCC19) Cohort Study

Author

Rivera, Donna R., primary, Peters, Solange, additional, Panagiotou, Orestis A., additional, Shah, Dimpy P., additional, Kuderer, Nicole M., additional, Hsu, Chih-Yuan, additional, Rubinstein, Samuel M., additional, Lee, Brendan J., additional, Choueiri, Toni K., additional, de Lima Lopes, Gilberto, additional, Grivas, Petros, additional, Painter, Corrie A., additional, Rini, Brian I., additional, Thompson, Michael A., additional, Arcobello, Jonathan, additional, Bakouny, Ziad, additional, Doroshow, Deborah B., additional, Egan, Pamela C., additional, Farmakiotis, Dimitrios, additional, Fecher, Leslie A., additional, Friese, Christopher R., additional, Galsky, Matthew D., additional, Goel, Sanjay, additional, Gupta, Shilpa, additional, Halfdanarson, Thorvardur R., additional, Halmos, Balazs, additional, Hawley, Jessica E., additional, Khaki, Ali Raza, additional, Lemmon, Christopher A., additional, Mishra, Sanjay, additional, Olszewski, Adam J., additional, Pennell, Nathan A., additional, Puc, Matthew M., additional, Revankar, Sanjay G., additional, Schapira, Lidia, additional, Schmidt, Andrew, additional, Schwartz, Gary K., additional, Shah, Sumit A., additional, Wu, Julie T., additional, Xie, Zhuoer, additional, Yeh, Albert C., additional, Zhu, Huili, additional, Shyr, Yu, additional, Lyman, Gary H., additional, and Warner, Jeremy L., additional

Published
2020
Full Text
View/download PDF

33. Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study

Author

Kuderer, Nicole M, primary, Choueiri, Toni K, additional, Shah, Dimpy P, additional, Shyr, Yu, additional, Rubinstein, Samuel M, additional, Rivera, Donna R, additional, Shete, Sanjay, additional, Hsu, Chih-Yuan, additional, Desai, Aakash, additional, de Lima Lopes, Gilberto, additional, Grivas, Petros, additional, Painter, Corrie A, additional, Peters, Solange, additional, Thompson, Michael A, additional, Bakouny, Ziad, additional, Batist, Gerald, additional, Bekaii-Saab, Tanios, additional, Bilen, Mehmet A, additional, Bouganim, Nathaniel, additional, Larroya, Mateo Bover, additional, Castellano, Daniel, additional, Del Prete, Salvatore A, additional, Doroshow, Deborah B, additional, Egan, Pamela C, additional, Elkrief, Arielle, additional, Farmakiotis, Dimitrios, additional, Flora, Daniel, additional, Galsky, Matthew D, additional, Glover, Michael J, additional, Griffiths, Elizabeth A, additional, Gulati, Anthony P, additional, Gupta, Shilpa, additional, Hafez, Navid, additional, Halfdanarson, Thorvardur R, additional, Hawley, Jessica E, additional, Hsu, Emily, additional, Kasi, Anup, additional, Khaki, Ali R, additional, Lemmon, Christopher A, additional, Lewis, Colleen, additional, Logan, Barbara, additional, Masters, Tyler, additional, McKay, Rana R, additional, Mesa, Ruben A, additional, Morgans, Alicia K, additional, Mulcahy, Mary F, additional, Panagiotou, Orestis A, additional, Peddi, Prakash, additional, Pennell, Nathan A, additional, Reynolds, Kerry, additional, Rosen, Lane R, additional, Rosovsky, Rachel, additional, Salazar, Mary, additional, Schmidt, Andrew, additional, Shah, Sumit A, additional, Shaya, Justin A, additional, Steinharter, John, additional, Stockerl-Goldstein, Keith E, additional, Subbiah, Suki, additional, Vinh, Donald C, additional, Wehbe, Firas H, additional, Weissmann, Lisa B, additional, Wu, Julie Tsu-Yu, additional, Wulff-Burchfield, Elizabeth, additional, Xie, Zhuoer, additional, Yeh, Albert, additional, Yu, Peter P, additional, Zhou, Alice Y, additional, Zubiri, Leyre, additional, Mishra, Sanjay, additional, Lyman, Gary H, additional, Rini, Brian I, additional, Warner, Jeremy L, additional, Abidi, Maheen, additional, Acoba, Jared D., additional, Agarwal, Neeraj, additional, Ahmad, Syed, additional, Ajmera, Archana, additional, Altman, Jessica, additional, Angevine, Anne H., additional, Azad, Nilo, additional, Bar, Michael H., additional, Bardia, Aditya, additional, Barnholtz-Sloan, Jill, additional, Barrow, Briana, additional, Bashir, Babar, additional, Belenkaya, Rimma, additional, Berg, Stephanie, additional, Bernicker, Eric H., additional, Bestvina, Christine, additional, Bishnoi, Rohit, additional, Boland, Genevieve, additional, Bonnen, Mark, additional, Bouchard, Gabrielle, additional, Bowles, Daniel W., additional, Busser, Fiona, additional, Cabal, Angelo, additional, Caimi, Paolo, additional, Carducci, Theresa, additional, Casulo, Carla, additional, Chen, James L., additional, Clement, Jessica M, additional, Chism, David, additional, Cook, Erin, additional, Curran, Catherine, additional, Daher, Ahmad, additional, Dailey, Mark, additional, Dahiya, Saurabh, additional, Deeken, John, additional, Demetri, George D., additional, DiLullo, Sandy, additional, Duma, Narjust, additional, Elias, Rawad, additional, Faller, Bryan, additional, Fecher, Leslie A., additional, Feldman, Lawrence E., additional, Friese, Christopher R., additional, Fu, Paul, additional, Fu, Julie, additional, Futreal, Andy, additional, Gainor, Justin, additional, Garcia, Jorge, additional, Gill, David M., additional, Gillaspie, Erin A., additional, Giordano, Antonio, additional, Glace, (Mary) Grace, additional, Grothey, Axel, additional, Gulati, Shuchi, additional, Gurley, Michael, additional, Halmos, Balazs, additional, Herbst, Roy, additional, Hershman, Dawn, additional, Hoskins, Kent, additional, Jain, Rohit K., additional, Jabbour, Salma, additional, Jha, Alokkumar, additional, Johnson, Douglas B., additional, Joshi, Monika, additional, Kelleher, Kaitlin, additional, Kharofa, Jordan, additional, Khan, Hina, additional, Knoble, Jeanna, additional, Koshkin, Vadim S., additional, Kulkarni, Amit A., additional, Lammers, Philip E., additional, Leighton, John C., additional, Lewis, Mark A., additional, Li, Xuanyi, additional, Li, Ang, additional, Lo, K.M. Steve, additional, Loaiza-Bonilla, Arturo, additional, LoRusso, Patricia, additional, Low, Clarke A., additional, Lustberg, Maryam B., additional, Mahadevan, Daruka, additional, Mansoor, Abdul-Hai, additional, Marcum, Michelle, additional, Markham, Merry Jennifer, additional, Handy Marshall, Catherine, additional, Mashru, Sandeep H., additional, Matar, Sara, additional, McNair, Christopher, additional, McWeeney, Shannon, additional, Mehnert, Janice M., additional, Menendez, Alvaro, additional, Menon, Harry, additional, Messmer, Marcus, additional, Monahan, Ryan, additional, Mushtaq, Sarah, additional, Nagaraj, Gayathri, additional, Nagle, Sarah, additional, Naidoo, Jarushka, additional, Nakayama, John M., additional, Narayan, Vikram, additional, Nelson, Heather H., additional, Nemecek, Eneida R., additional, Nguyen, Ryan, additional, Nuzzo, Pier Vitale, additional, Oberstein, Paul E., additional, Olszewski, Adam J., additional, Owenby, Susie, additional, Pasquinelli, Mary M., additional, Philip, John, additional, Prabhakaran, Sabitha, additional, Puc, Matthew, additional, Ramirez, Amelie, additional, Rathmann, Joerg, additional, Revankar, Sanjay G., additional, Rho, Young Soo, additional, Rhodes, Terence D., additional, Rice, Robert L., additional, Riely, Gregory J., additional, Riess, Jonathan, additional, Rink, Cameron, additional, Robilotti, Elizabeth V., additional, Rosenstein, Lori, additional, Routy, Bertrand, additional, Rovito, Marc A., additional, Saif, M. Wasif, additional, Sanyal, Amit, additional, Schapira, Lidia, additional, Schwartz, Candice, additional, Serrano, Oscar, additional, Shah, Mansi, additional, Shah, Chintan, additional, Shaw, Grace, additional, Shergill, Ardaman, additional, Shouse, Geoffrey, additional, Soares, Heloisa P., additional, Solorzano, Carmen C., additional, Srivastava, Pramod K., additional, Stauffer, Karen, additional, Stover, Daniel G., additional, Stratton, Jamie, additional, Stratton, Catherine, additional, Subbiah, Vivek, additional, Tamimi, Rulla, additional, Tannir, Nizar M., additional, Topaloglu, Umit, additional, Van Allen, Eli, additional, Van Loon, Susan, additional, Vega-Luna, Karen, additional, Venepalli, Neeta, additional, Verma, Amit K., additional, Vikas, Praveen, additional, Wall, Sarah, additional, Weinstein, Paul L., additional, Weiss, Matthias, additional, Wise-Draper, Trisha, additional, Wood, William A., additional, Xu, Wenxin (Vincent), additional, Yackzan, Susan, additional, Zacks, Rosemary, additional, Zhang, Tian, additional, Zimmer, Andrea J., additional, and West, Jack, additional

Published
2020
Full Text
View/download PDF

40. Preoperative CHA2 DS2 -VASc Score Predicts Postoperative Atrial Fibrillation after Lobectomy.

Author

Lee, Charles T., Strauss, David M., Stone, Lauren E., Stoltzfus, Jill C., Puc, Matthew M., and Burfeind, William R.

Subjects
LOBECTOMY (Lung surgery), ATRIAL fibrillation
Abstract

Background Postoperative atrial fibrillation (POAF) affects 10 to 20% of noncardiac thoracic surgeries and increases patient morbidity and costs. The purpose of this study is to determine if preoperative CHA2 DS2-VASc score can predict POAF after pulmonary lobectomy for nonsmall cell lung cancer. Methods Patients with complete CHA2 DS2-VASc data who underwent lobectomies from January 2007 to January 2016 at a single institution were analyzed in a retrospective case–control study using a prospective database. An independent samples t -test was used to compare the mean CHA2 DS2-VASc scores of POAF and non-POAF groups. A multivariable logistic regression analysis (MVA) evaluated the independent contribution of variables of the CHA2 DS2-VASc score in predicting POAF. Chi-square test with univariate odds ratios (ORs) was used to determine a statistically significant cutoff score for predicting POAF. Results Of 525 total patients, 82 (15.6%) developed POAF (mean CHA2 DS2-VASc score: 2.7) and 443 (84.4%) did not develop POAF (mean score: 2.3). Mean difference between these groups was significant at 0.43 (p = 0.01; 95% confidence interval [CI]: 0.09–0.76). In the MVA, significant predictors of POAF were age 65 to 74 years (adjusted OR [aOR] = 2.45; 95% CI: 1.31–4.70; p = 0.006) and age ≥75 years (aOR = 3.11; 95% CI: 1.62–5.95; p = 0.0006). Patients with CHA2 DS2-VASc scores ≥5 had significantly increased OR for POAF (OR = 2.59; 95% CI: 1.22–5.50). Conclusions Preoperatively calculated CHA2 DS2-VASc score can predict POAF in patients undergoing pulmonary lobectomy. Age is the most statistically significant independent predictor, and patients with scores ≥5 have significantly increased risk. Trials for POAF prophylaxis should target this population. [ABSTRACT FROM AUTHOR]

Published
2019
Full Text
View/download PDF

45. Inflammatory response after bioglue application: Reply

Author

Hewitt, Charles W., primary, Marra, Steven W., additional, Kann, Brian R., additional, Tran, Hoang S., additional, Puc, Matthew M., additional, Chrzanowski, Frank A., additional, Tran, Jean-Luc V., additional, Cilley, Jonathan H., additional, Simonetti, Vincent A., additional, DelRossi, Anthony J., additional, and Lenz, Steven D., additional

Published
2002
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results